The patient commenced olanzapine 20 mg daily, along with participation in an outpatient dual-diagnosis program. Three months later, paroxetine 20 mg daily was added for major depression, together with maintenance diazepam for withdrawal symptoms. The frequency of polysubstance use decreased gradually over the following year. At annual follow-up, parkinsonism (that is, postural rigidity, left upper extremity tremor, and rigidity without TD occurrence) was observed and recorded according to the Extrapyramidal Symptom Rating Scale (ESRS) (5) . During the subsequent year, diazepam was tapered, and topiramate 300 mg daily was added for mood stabilization. Olanzapine was gradually increased to 40 mg daily to decrease residual psychotic symptoms. The polysubstance use became sporadic. At second-year follow-up, the ESRS elicited new jaw TD with previously stable parkinsonism. Owing to ongoing psychotic symptoms, we did not attempt any pharmacotherapy changes. Currently, the patient is not bothered by TD and continues pharmacotherapy. Illicit substance use remains a concern.
Animal studies suggest that olanzapine's low TD potential may be owing to selectivity for basal ganglia nuclei, along with selective nucleic acid expression in the thalamic reticular nucleus (6). By contrast, typical antipsychotics appear nonselective: they broadly affect basal ganglia, causing changes in the substantia nigra and mediodorsal nucleus while also altering thalamic reticular nucleus gene expression. This nonselectivity could explain TD occurrence following chronic antipsychotic exposure (6) . Apart from high dosages, alcohol abuse (4) and neurological disease (7) may be other risk factors for TD occurrence with atypical antipsychotics. Our patient was receiving high-dosage olanzapine, partly to decrease psychotic symptoms and partly because of his male sex and cigarette smoking, both of which decrease olanzapine levels (8) . Vigilance for TD with atypical antipsychotics is warranted in schizophrenia patients with comorbid substance dependence.
Re: Depression, Stroke Diagnosis, and SSRI Discontinuation Syndrome
Dear Editor:
Dr Ramassubu reports the case of a man aged 67 years who on 2 separate occasions 4 months apart developed anxiety, agitation, irritability, confusion, gait ataxia, and bilateral motor weakness on stopping paroxetine (1). On both occasions, symptoms remitted within 48 hours of his restarting paroxetine. The patient had multiple risk factors for multiinfarct dementia (that is, hypertension, diabetes, and coronary artery disease) and a history of memory problems. Following the first episode, magnetic resonance imaging (MRI) showed ischemic changes in the vertebrobasilar region, and angiography revealed mild occlusion or hypoplasia of part of the anterior cerebral artery. Repeat MRI after the second episode revealed no progression of the ischemic changes. Dr Ramassubu suggests that the 2 episodes of ataxia and motor weakness may reflect minor strokes caused by paroxetine discontinuation. We think this is highly improbable. The most likely explanation is that the patient experienced 2 episodes of paroxetine discontinuation syndrome and that the MRI changes are coincidental, perhaps reflecting early multiinfarct dementia for which this patient had multiple risk factors.
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